Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313930 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10507979 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL11304206 | 0.79 | ALDH1A1 (0.59) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL16426789 | 0.78 | FFAR3 (0.41) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10887665 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL3631729 | 0.76 | ALDH1A1 (0.71) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL1743259 | 0.75 | TLR4 (0.32) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL9193723 | 0.74 | ALDH1A1 (0.53) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL9298979 | 0.74 | MAPT (0.55) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10886851 | 0.72 | ALDH1A1 (0.51) | ALDH1A1MAPTKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093227-B2 | Monosaccharide compounds and methods therefor | ALCHEMIA PTY LTD (AU) | 2012-01-10 | — | — | US | disclosed |
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | ALCHEMIA PTY LTD. (AU) | 2010-07-22 | — | — | US | disclosed |
| EP-1326873-A4 | COMBINATORIAL LIBRARIES OF MONOSACCHARIDES | ALCHEMIA PTY LTD (AU) | 2007-12-19 | — | — | EP | disclosed |
| EP-1326873-A1 | COMBINATORIAL LIBRARIES OF MONOSACCHARIDES | Alchemia Pty Ltd (AU) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002032915-A1 | COMBINATORIAL LIBRARIES OF MONOSACCHARIDES | ALCHEMIA PTY LTD (AU) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184607-A1 | MONOSACCHARIDE COMPOUNDS AND METHODS THEREFOR | SLC5A1, UGGT1, MRPL21 | ALDH1A1 912/4885MAPT 4099/4885KDM4E 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.